분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-08-14 15:32:16 , Hit : 810
 Gene Study Based on RNA Interference May Lead to New Liver Cancer Therapies

http://www.genengnews.com/gen-news-highlights/gene-study-based-on-rna-interference-may-lead-to-new-liver-cancer-therapies/81254796?utm_medium=newsletter&utm_source=GEN+Daily+News+Highlights&utm_content=01&utm_campaign=GEN+Daily+News+Highlights_20170811


GEN News Highlights
More »
August 11, 2017

    
University of Maryland researchers think they've discovered how a specific gene plays a key role in helping liver cancer cells obtain the nutrition necessary to proliferate. Their study (“Silencing of Solute Carrier Family 13 Member 5 Disrupts Energy Homeostasis and Inhibits Proliferation of Human Hepatocarcinoma Cells”) appears in the Journal of Biological Chemistry.

Cancer is often treated by starving it by targeting the pathways cancer cells use to meet their energy needs. The laboratory of Hongbing Wang, Ph.D., focuses on this approach as it applies to liver cancer.

“The solute carrier family 13 member 5 (SLC13A5), a sodium-coupled citrate transporter, plays a key role in importing citrate from the circulation into liver cells,” write the investigators. “Here, we sought to determine whether SLC13A5 regulates hepatic energy homeostasis and proliferation of hepatoma cells.  RNAi-mediated silencing of SLC13A5 expression in two human hepatoma cell lines, HepG2 and Huh7, profoundly suppressed cell proliferation and colony formation, and induced cell cycle arrest accompanied by increased expression of cyclin-dependent kinase inhibitor p21 and decreased expression of cyclin B1."

“…our findings expand the role of SLC13A5 from facilitating hepatic energy homeostasis to influencing hepatoma cell proliferation and suggest a potential role of SLC13A5 in the progression of human hepatocellular carcinoma.”

"The liver is one of the most busy, active organs in the body," Dr. Wang said, so the healthy liver already needs a lot of energy. In addition, liver cancer appears to be one of the few cancers of which incidences seem to be on the rise, possibly in association with the rise of metabolism-related conditions such as nonalcoholic fatty liver disease.

When looking for genes that might play important roles in the metabolism of healthy and cancerous liver cells, Dr. Wang and his colleagues became interested in a gene called SLC13A5, which produces a protein that transports citrate into cells. SLC13A5 is expressed mainly in the liver, but its role is relatively understudied.

"If you search for SLC13A5 in PubMed—I searched this morning—there are 54 publications, which is not a whole lot," noted Dr. Wang. Nearly half of these studies were published in the last two years. Research on SLC13A5 has focused on its role in obesity and diabetes; knocking out the SLC13A5 gene in mice prevents high-fat diet-induced obesity. If this gene plays a role in energy homeostasis and energy balance in the context of obesity, Dr. Wang reasoned, perhaps it could play a role in the energy requirements of liver cancer cells.

Zhihui Li, Ph.D., a postdoctoral fellow in Wang's lab, performed experiments in which he used RNA interference (RNAi) to suppress (but not completely eliminate) the production of the SLC13A5 protein. He carried out these experiments in cultures of two human hepatocellular carcinoma cell lines. Suppressing SLC13A5 resulted in liver cancer cells that did not die but had significantly slower growth and division. Similarly, when these cells were injected into mice, the cells in which SLC13A5 was suppressed formed barely discernable tumors compared to the unmanipulated cancer cells.

Dr. Wang hypothesizes that the extracellular citrate taken up by the SLC13A5 protein is required by the liver cancer cells for fatty acid synthesis. Because prostate cancer does not express SLC13A5, the growth of prostate cancer cells was unaffected by suppressing SLC13A5 expression. The fact that prostate cancer grew independently of the presence of SLC13A5 supports the idea that different cancers use different methods to meet their high energy requirements.

Dr. Wang emphasizes that this work is preliminary and that comparing SLC13A5 activity in healthy and cancerous human liver tissue will be necessary before studies of this pathway as a cancer drug target should be contemplated.








1067   Foamy 바이러스 벡터를 이용한 유전자 치료  이성욱 2008/02/12 5778
1066   Foot-and-mouth culls could be cut  이성욱 2011/05/11 3156
1065   Former Reginans changing the future of HIV  이성욱 2011/12/28 2257
1064   Fragile X syndrome: Trigger for most common form of intellectual disability and autism uncovered  이성욱 2014/03/05 1771
1063   Frances H. Arnold, George P. Smith, and Gregory P. Winter share 2018 Nobel Prize in Chemistry  이성욱 2018/10/04 358
1062   Friends connect on a genetic level  이성욱 2011/01/24 2262
1061   From Startups to Moguls] CRISPR 유전자가위 없이 편집한다? Homology Medicines  이성욱 2017/09/11 606
1060   Gene Editing Treats Blood Disease  이성욱 2011/07/16 3017
  Gene Study Based on RNA Interference May Lead to New Liver Cancer Therapies  이성욱 2017/08/14 810
1058   Gene Therapy Allows Beethoven Mouse to Hear  이성욱 2015/07/10 875
1057   Gene Therapy Appears to Help Patient With Anemia  이성욱 2010/09/17 2909
1056   Gene therapy drug approval granted to GSK  이성욱 2016/05/30 935
1055   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 334
1054   Gene Therapy for Controlling HIV Shows Early Promise  이성욱 2014/03/08 1600
1053   Gene Therapy for Immune Disorder Lasts Nine Years, Two New Studies Show  이성욱 2011/08/25 2479
1052   Gene Therapy May Thwart HIV  이성욱 2011/09/23 2056
1051   Gene therapy offers hope for Parkinson's disease  이성욱 2011/03/23 2353
1050   Gene Therapy Shows Promise Against Age-Related Macular Degeneration  이성욱 2011/05/04 2542
1049   Gene Therapy Shows Promise as Hemophilia Treatment in Animal Studies  이성욱 2011/11/10 2435
1048   Gene therapy trial on hold  이성욱 2007/08/07 4978

[이전 10개] [1].. 11 [12][13][14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN